Notice of Intent to Publish a Funding Opportunity Announcement for Advancing Research on Mechanisms and Management of Pain for Diseases and Conditions within NIDDK Mission Areas (R01 Clinical Trial Optional)
Notice Number:

Key Dates

Release Date:
February 07, 2023
Estimated Publication Date of Funding Opportunity Announcement:
March 03, 2023
First Estimated Application Due Date:
May 04, 2023
Earliest Estimated Award Date:
September 01, 2023
Earliest Estimated Start Date:
December 01, 2023
Related Announcements


Issued by

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)


The purpose of this Notice is to inform the community that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) intends to publish a Funding Opportunity Announcement (FOA) that will solicit broad investigator-initiated research projects proposing novel basic, translational, and clinical studies and efforts to develop new approaches to assess and treat pain for disorders within the NIDDK mission areas. 

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This will be an open competition.

The FOA is expected to be published in Winter 2023 with an expected application due date in Spring 2023.

This FOA will utilize the R01 activity code. Details of the planned FOA are provided below.

Research Initiative Details

Pain is a common and often debilitating symptom of numerous diseases and conditions and results in broad morbidity and a greatly diminished quality of life. While pain affects men and women of all ages, women are at greater risk of developing chronic pain conditions than men and pain is especially prevalent in the elderly. In addition, pain can be particularly impactful to underserved populations due to inadequate healthcare.

The impact of pain on patient quality of life for diseases and conditions within the mission of the NIDDK is enormous. However, for these conditions there is an insufficient understanding of the underlying biological and clinical contributors of pain. In addition, new clinical management strategies that better measure, predict, and target pain and improve upon current interventions, such as opioid therapy, are critically needed for affected patients. To accelerate critical advances in defining and treating pain in NIDDK mission areas additional, broad research efforts are critically needed.

To address these needs the planned FOA will invite investigator-initiated applications designed to address critical questions of pain as a component of diabetic neuropathy; digestive diseases, nutritional disorders, and obesity; and kidney, urologic, and hematologic diseases. This Notice encourages investigators with expertise and insights into these areas to begin to consider applying for this new FOA.

In addition, collaborative investigations combining expertise will also be encouraged.

Information gained is expected to significantly advance the characterization of pain as a defining symptom for relevant diseases and disorders within NIDDK mission interests, as well as inform new clinical strategies for improving pain management and outcomes in affected patient populations. Studies proposing multi-disciplinary approaches and diverse expertise, that follow upon recent advances, and leverage unique methodologies or resources will be encouraged.

Funding Information
Estimated Total Funding

The NIDDK intends to commit approximately $2.5 million to this Program in Fiscal Year 2023 

Expected Number of Awards
Estimated Award Ceiling

The total annual costs for individual awards is expected to vary, depending on the scope of the project and the number of participating institutions. Application budgets are not limited but need to reflect the actual needs of the proposed projects. The maximum award period is 5 years. 

Primary Assistance Listing Number(s)


Anticipated Eligible Organizations
Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
Indian/Native American Tribal Government (Federally Recognized)
County governments
Independent school districts
Public housing authorities/Indian housing authorities
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Non-domestic (non-U.S.) Entity (Foreign Organization)
Regional Organization
Eligible Agencies of the Federal Government

Applications are not being solicited at this time. 


Please direct all inquiries to:

Chris Mullins, Ph.D.
Division of Kidney, Urologic, and Hematologic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-451-4902

Dana K. Andersen, M.D.
Division of Digestive Diseases and Nutrition
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 410-868-0638

Ashley Xia, M.D., Ph.D.
Division of Diabetes, Endocrinology, and Metabolic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-480-9505